Liman Huo
Biographic Data
| ID | 9999436 |
|---|---|
| NAME | Liman Huo |
| GIVEN NAMES | Liman |
| FAMILY NAME | Huo |
| SIGNATURE | HUO L |
| AFFILIATIONS | Hebei Medical University |
| ORCID | 0000-0003-0078-4047 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
Background: Sacituzumab tirumotecan (Sac-TMT) has demonstrated survival benefits over chemotherapy in patients with previously treated metastatic triple-negative breast cancer (mTNBC). However, its economic value under different payment contexts in China remains uncertain. Methods: A state-transition (Markov) model was used to estimate lifetime costs and quality-adjusted life-years (QALYs) for Sac-TMT versus single-agent chemotherapy in second-li…
No prominent works on this page.
Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
Background: Sacituzumab tirumotecan (Sac-TMT) has demonstrated survival benefits over chemotherapy in patients with previously treated metastatic triple-negative breast cancer (mTNBC). However, its economic value under different payment contexts in China remains uncertain. Methods: A state-transition (Markov) model was used to estimate lifetime costs and quality-adjusted life-years (QALYs) for Sac-TMT versus single-agent chemotherapy in second-li…
Advanced Breast Cancer Therapies (1 work) · Breast cancer (1 work) · Breast Cancer Treatment Studies (1 work) · Cancer Treatment and Pharmacology (1 work) · China (1 work) · List price (1 work) · Metastatic breast cancer (1 work) · Payment (1 work) · Reimbursement (1 work) · Willingness to pay (1 work)